Identification of a PCSK9-LDLR disruptor peptide with in vivo function

被引：32

作者：

Brousseau, Margaret E. ^{[1
]}

Clairmont, Kevin B. ^{[1
]}

Spraggon, Glen ^{[2
]}

Flyer, Alec N. ^{[1
]}

Golosov, Andrei A. ^{[1
]}

Grosche, Philipp ^{[3
]}

Amin, Jakal ^{[1
]}

Andre, Jerome ^{[3
]}

Burdick, Debra ^{[1
]}

Caplan, Shari ^{[1
]}

Chen, Guanjing ^{[1
]}

Chopra, Raj ^{[1
]}

Ames, Lisa ^{[1
]}

Dubiel, Diana ^{[1
]}

Fan, Li ^{[1
]}

Gattlen, Raphael ^{[3
]}

Kelly-Sullivan, Dawn ^{[1
]}

Koch, Alexander W. ^{[1
]}

Lewis, Ian ^{[3
]}

Li, Jingzhou ^{[1
]}

Liu, Eugene ^{[1
]}

Lubicka, Danuta ^{[1
]}

Marzinzik, Andreas ^{[3
]}

Nakajima, Katsumasa ^{[1
]}

Nettleton, David ^{[1
]}

Ottl, Johannes ^{[3
]}

Pan, Meihui ^{[1
]}

Patel, Tajesh ^{[1
]}

Perry, Lauren ^{[1
]}

Pickett, Stephanie ^{[3
]}

Poirier, Jennifer ^{[1
]}

Reid, Patrick C. ^{[4
]}

Pelle, Xavier ^{[3
]}

Seepersaud, Mohindra ^{[1
]}

Subramanian, Vanitha ^{[1
]}

Vera, Victoria ^{[1
]}

Xu, Mei ^{[1
]}

Yang, Lihua ^{[1
]}

Yang, Qing ^{[1
]}

Yu, Jinghua ^{[1
]}

Zhu, Guoming ^{[1
]}

Monovich, Lauren G. ^{[1
]}

机构：

[1] Novartis Inst BioMed Res, 22 Windsor St & 181 Massachusetts Ave, Cambridge, MA 02139 USA

[2] Novartis Res Fdn, Genom Inst, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA

[3] Novartis Inst BioMed Res, Fabrikstr 2,Novartis Campus, CH-4056 Basel, Switzerland

[4] PeptiDream Inc, Meguro Ku, KOL Bldg,Room 405,4-6-1 Komaba, Tokyo 1538904, Japan

来源：

CELL CHEMICAL BIOLOGY | 2022年 / 29卷 / 02期

关键词：

SMALL-MOLECULE INHIBITORS; FACTOR-LIKE REPEAT; CRYSTAL-STRUCTURE; ANNEXIN A2; PROTEIN; DESIGN; BINDING; ANTIBODIES; DISPLAY; SITE;

D O I：

10.1016/j.chembiol.2021.08.012

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates plasma low-density lipoprotein cholesterol (LDL-C) levels by promoting hepatic LDL receptor (LDLR) degradation. Therapeutic antibodies that disrupt PCSK9-LDLR binding reduce LDL-C concentrations and cardiovascular disease risk. The epidermal growth factor precursor homology domain A (EGF-A) of the LDLR serves as a primary contact with PCSK9 via a flat interface, presenting a challenge for identifying small molecule PCSK9-LDLR disruptors. We employ an affinity-based screen of 10(13) in vitro-translated macrocyclic peptides to identify high-affinity PCSK9 ligands that utilize a unique, induced-fit pocket and partially disrupt the PCSK9-LDLR interaction. Structure-based design led to molecules with enhanced function and pharmacokinetic properties (e.g., (13)PCSK9i). In mice,(13)PCSK9i reduces plasma cholesterol levels and increases hepatic LDLR density in a dose-dependent manner. (13)PCSK9i functions by a unique, allosteric mechanism and is the smallest molecule identified to date with in vivo PCSK9-LDLR disruptor function.

引用

页码：249 / +

页数：16

共 50 条

[31] PCSK9 Prosegment Chimera as Novel Inhibitors of LDLR Degradation
Saavedra, Yascara Grisel Luna
Zhang, Jianbing
Seidah, Nabil G.
PLOS ONE, 2013, 8 (08):
[32] PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
Lagace, Thomas A.
CURRENT OPINION IN LIPIDOLOGY, 2014, 25 (05) : 387 - 393
[33] A systematic review of LDLR, PCSK9, and APOB variants in Asia
Mahdieh, Nejat
Heshmatzad, Katayoun
Rabbani, Bahareh
ATHEROSCLEROSIS, 2020, 305 : 50 - 57
[34] Associations Between Soluble LDLR and Lipoproteins in a White Cohort and the Effect of PCSK9 Loss-of-Function
Mayne, Janice
Ooi, Teik Chye
Tepliakova, Lioudmila
Seebun, Deeptee
Walker, Krystal
Mohottalage, Dhanuddara
Ning, Zhibin
Abujrad, Hussein
Mbikay, Majambu
Wassef, Hanny
Chretien, Michel
Figeys, Daniel
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 103 (09): : 3486 - 3495
[35] Lunasin functionally enhances LDL uptake via inhibiting PCSK9 and enhancing LDLR expression in vitro and in vivo
Gu, Lili
Wang, Yue
Xu, Yaqiong
Tian, Qinghua
Lei, Gaoxin
Zhao, Cheng
Gao, Zhan
Pan, Qin
Zhao, Wenfeng
Nong, Liu
Tan, Shuhua
ONCOTARGET, 2017, 8 (46) : 80826 - 80840
[36] A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
Gupta, Nidhi
Fisker, Niels
Asselin, Marie-Claude
Lindholm, Marie
Rosenbohm, Christoph
Orum, Henrik
Elmen, Joacim
Seidah, Nabil G.
Straarup, Ellen Marie
PLOS ONE, 2010, 5 (05):
[37] Inhibition of PCSK9D374Y/LDLR Protein-Protein Interaction by Computationally Designed T9 Lupin Peptide
Lammi, Carmen
Sgrignani, Jacopo
Roda, Gabriella
Arnoldi, Anna
Grazioso, Giovanni
ACS MEDICINAL CHEMISTRY LETTERS, 2019, 10 (04): : 425 - +
[38] THE ROLE OF CAP1 IN PCSK9 REGULATION OF LDLR LEVELS
Seidah, Nabil
Gaillard, Carole Fruchart
Ouadda, Ali Ben Djoudi
HEPATOLOGY, 2021, 74 : 295A - 295A
[39] PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis
Arida, Aikaterini
Legaki, Aigli-Ioanna
Kravvariti, Evrydiki
Protogerou, Athanasios
Sfikakis, Petros P.
Chatzigeorgiou, Antonios
FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
[40] CHARACTERIZATION OF THE EFFECTS OF FAMILIAL HYPERCHOLESTEROLEMIA MUTATIONS IN LDLR ON PCSK9 BINDING
Deng, Shijun
Alabi, Adekunle
Zhang, Dawei
ATHEROSCLEROSIS SUPPLEMENTS, 2018, 32 : 55 - 55

← 1 2 3 4 5 →